# Clinical Utility of Pharmacogenomics of Psychotropic Medications

> **NCT03907124** · PHASE4 · WITHDRAWN · sponsor: **Oregon Health and Science University**

## Conditions studied

- Psychiatric Disorders
- Pain

## Interventions

- **DRUG:** Genetically-guided treatment with FDA-approved psychotropic drugs
- **DRUG:** Treatment as usual (TAU)

## Key facts

- **NCT ID:** NCT03907124
- **Lead sponsor:** Oregon Health and Science University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-06-03
- **Primary completion:** 2021-07-09
- **Final completion:** 2021-07-09
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** PI left institution prior to recruitment.
- **Last updated:** 2023-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03907124

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03907124, "Clinical Utility of Pharmacogenomics of Psychotropic Medications". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03907124. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*